Home » News » Clinical Intelligence » FDA approves BioSante’s Bio-T-Gel

FDA approves BioSante’s Bio-T-Gel

Wednesday, February 15, 2012

The FDA has approved Bio-T-Gel for the treatment of male hypogonadism (low testosterone levels), according to BioSante Pharmaceuticals.

The testosterone gel was initially developed by BioSante and then licensed to Teva Pharmaceutical for late-stage clinical development. Teva is responsible for all Bio-T-Gel regulatory and marketing activities. BioSante will receive royalties and may receive certain milestone payments upon commercialization of Bio-T-Gel. The current U.S. market for male testosterone products is estimated at over $1.6 billion.

“We are pleased that Bio-T-Gel will provide another treatment option to men suffering from low testosterone levels,” said Stephen M. Simes, BioSante’s president and CEO. “We are confident that Teva has the commercialization and marketing expertise to implement a successful launch, and we look forward to Bio-T-Gel reaching the market.”

This news comes just weeks after the FDA rejected two of BioSante’s critical late-stage female libido gels.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!